Lora Brown
Internal Medicine · Gahanna, OHNPI 1770634701
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,235 and has fallen 97.6% since, to $29 in 2025. Among internal medicine clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $12.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$564
- AstraZeneca$491
- Merck$458
- Novo Nordisk$419
- Amarin Pharma, Inc.$254
- GSK$210
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,33798%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $564 |
| AstraZeneca | 29 | $491 |
| Merck | 52 | $458 |
| Novo Nordisk | 43 | $419 |
| Amarin Pharma, Inc. | 29 | $254 |
| GSK | 13 | $210 |
| Lilly USA, LLC | 13 | $189 |
| Abbott | 10 | $182 |
| Sanofi-aventis U.S. LLC | 12 | $160 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $142 |
| Pfizer | 8 | $125 |
| Exact Sciences | 6 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $123 |
| Amgen | 7 | $102 |
| Bayer | 5 | $88 |
| QOL Medical, LLC | 4 | $85 |
| Astellas Pharma US Inc | 5 | $77 |
| Novartis | 4 | $64 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $63 |
| Kowa Pharmaceuticals America, Inc. | 5 | $63 |
| Boehringer Ingelheim | 4 | $54 |
| Johnson & Johnson | 3 | $53 |
| Endo Pharmaceuticals Inc. | 3 | $51 |
| Shield Therapeutics Inc | 3 | $49 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Mayne Pharma Commercial LLC | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Neos Therapeutics, LP | 1 | $18 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Alfasigma USA, Inc. | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $10 |
How this compares
$4,431 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 20 | $732 |
| Atorvastatin Calcium | 35 | $463 |
| Pantoprazole Sodium | 14 | $420 |
| Losartan Potassium | 30 | $310 |
| Levothyroxine Sodium | 42 | $277 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $225 |
| Simvastatin | 11 | $165 |
| Spironolactone | 11 | $163 |
| Amlodipine Besylate | 33 | $141 |
| Omeprazole | 18 | $139 |
| Rosuvastatin Calcium | 23 | $124 |
| Duloxetine Hcl | 13 | $122 |
| Carvedilol | 14 | $106 |
| Gabapentin | 13 | $96 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Gahanna
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
- Richard KimDayton$326K
- Marina MagreyCleveland$312K
- Lisa LarkinCincinnati$276K
- Gregg FaimanMayfield Hts$274K
- Vincent MartinCincinnati$261K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.